login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
TRAVERE THERAPEUTICS INC (TVTX) Stock News
USA
- NASDAQ:TVTX -
US89422G1076
-
Common Stock
32.34
USD
-0.96 (-2.88%)
Last: 11/7/2025, 8:23:13 PM
32.34
USD
0 (0%)
After Hours:
11/7/2025, 8:23:13 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
TVTX Latest News, Press Relases and Analysis
All
Press Releases
10 days ago - By: Chartmill
Travere Therapeutics Inc (NASDAQ:TVTX) Q3 2025 Earnings Soar, Fueled by FILSPARI Sales and Milestone Payments
3 days ago - By: Travere Therapeutics, Inc.
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
5 days ago - By: Travere Therapeutics, Inc.
Travere Therapeutics to Participate at Upcoming Investor Conferences
9 days ago - By: Investor's Business Daily
Top 2% Travere Looks To Top Buy Zone After Screaming Up Another Beat
10 days ago - By: Travere Therapeutics, Inc.
Travere Therapeutics Reports Third Quarter 2025 Financial Results
10 days ago - By: Benzinga
- Mentions:
IR
CDP
ENTG
BUD
...
Earnings Scheduled For October 30, 2025
17 days ago - By: Travere Therapeutics, Inc.
Travere Therapeutics to Report Third Quarter 2025 Financial Results
23 days ago - By: Travere Therapeutics, Inc.
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025
a month ago - By: Travere Therapeutics, Inc.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
a month ago - By: Travere Therapeutics, Inc.
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
a month ago - By: Vifor International AG (CSL Vifor)
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
2 months ago - By: Benzinga
The Analyst Verdict: Travere Therapeutics In The Eyes Of 9 Experts
2 months ago - By: Travere Therapeutics, Inc.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 months ago - By: Investor's Business Daily
Why Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year High
2 months ago - By: Stocktwits
- Mentions:
VTI
IWM
Travere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug Application
2 months ago - By: Travere Therapeutics, Inc.
Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS
2 months ago - By: Travere Therapeutics, Inc.
Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism
2 months ago - By: Investor's Business Daily
Travere Flirts With A Breakout As FDA Decision Bolsters Filspari's Launch
2 months ago - By: Travere Therapeutics, Inc.
Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy
3 months ago - By: Travere Therapeutics, Inc.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: Zacks Investment Research
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings
3 months ago - By: Zacks Investment Research
- Mentions:
ALVO
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
3 months ago - By: Travere Therapeutics, Inc.
Travere Therapeutics Reports Second Quarter 2025 Financial Results
Please enable JavaScript to continue using this application.